-
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a revenue of RMB 1.206 billion (USD 166.3 million), a 1.61% year-on-year (YOY) increase. Operating profit reached RMB 661 million (USD 91.1 million), up 15.22% YOY, while net profit was RMB 502 million (USD 69.2 million),…
-
MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment
•
Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has received marketing approval from China’s National Medical Products Administration (NMPA). The approval is for the minimally invasive interventional treatment of thoracic aortic dissection involving branches of the aortic arch. Product InnovationThe Cratos system represents an…
-
MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award
•
The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards, with Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Castor® branched aortic stent graft and delivery system receiving the China Patent Gold Award. The awarded patent, titled “Branched Covered Stent, Including Its Delivery System and…
-
Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced the commencement of a pre-marketing clinical study for its polyvinyl alcohol embolic microspheres. The company has completed the first pre-marketing clinical implantation in transcatheter arterial chemoembolization (TACE) surgery for left lobe lesions in patients with…
-
MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National Medical Products Administration (NMPA) for its fiber wool plug spring coil, a device used for the filling treatment of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas. The spring coil is constructed from a platinum…
-
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported its financial results for the first half of 2024, demonstrating robust growth. The company’s revenue reached RMB 787 million, marking a 26.63% increase year-on-year (YOY). The operating profit soared to RMB 472 million, a 44.46%…
-
Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions
•
Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai Stock Exchange (SHA: 688016), has received a Category III medical device license from China’s National Medical Products Administration (NMPA) for its venous stent system. This product was granted special review status as an innovative medical…
-
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
•
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and international, have revised the pricing of their thoracic aortic stent graft products. Among these companies are the US-Irish firm Medtronic (NYSE: MDT), Shanghai-based MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), W. L. Gore & Associates,…
-
MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments
•
SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device industry, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its ReeAmber peripheral balloon dilation catheter. This next-generation device is designed to address a broad spectrum of vascular…
-
NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System
•
BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the pricing of Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Castor aortic stent graft and delivery system. The NHSA’s inquiry comes after reports from the public highlighted the artificially high prices of the product. According…
-
MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology sector, has secured a significant regulatory milestone with its aortic occlusion balloon catheter receiving marketing approval from China’s National Medical Products Administration (NMPA). This product, designed for temporary blood flow obstruction in the aorta, marks…
-
MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Vepack filter retriever. The Vepack system, comprising a catcher and a sheath/expander, is designed to percutaneously remove…
-
MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has declared its intention for its wholly-owned subsidiary, MicroPort Endovastec B.V., to acquire a controlling 72.37% stake in Optimum Medical Device Inc. (OMD) for a transaction valued at USD 65 million. Following the completion of this…
-
MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced that its Vewatch vena cava filter has received approval from the National Medical Products Administration (NMPA) for the prevention of pulmonary embolism caused by thrombus detachment in the inferior vena cava system. This product marks…
-
MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in China, has announced that it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its newly developed vena cava filter. This device is designed to be percutaneously inserted…
-
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth forecast for its subsidiary Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), in which it holds a 40.32% stake. MicroPort Endovascular is anticipated to achieve revenues within the range of RMB 1.17-1.2 billion (USD 168-238…
-
MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion
•
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up to RMB 1.809 billion (USD 260 million) through a private placement of 21,593,444 shares. The funds raised will be allocated to several key areas, including the construction of global headquarters and the advancement of innovation…
-
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
•
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB 2.55 billion (USD 378 million) via a private placement. The proceeds will be used to fund several strategic initiatives, including the development of its global headquarters and innovation and industrialization plan projects, research into peripheral…
